| Abstract |
【Abstract】Objective：Analyze the influencing factors of disease benefit in patients with malignant hematological diseases.Methods：From July 2020 to June 2023, 112 patients with malignant hematological diseases were selected and clinical data were collected. The Chinese adapted version of the Cancer Patient Disease Benefit Scale (BFS-A), the Chinese version of the Cancer Self Management Efficacy Scale (SUPPH), and the Self Perceived Burden Scale (SPBS) were used to evaluate disease benefit, self-management efficacy, and disease burden. BFS-A scores were compared with different clinical data, and the correlation between BFS-A scores and SUPPH and SPBS scores was analyzed, And multiple linear regression was used to analyze the influencing factors of disease benefit.Result：The scores of FFS-A, SUPPH, and SPBS were (58.01 ± 11.19), (68.00 ± 19.97), and (30.00 ± 4.90), respectively. The FFS-A scores of occupation, family annual income, who paid for the hospitalization expenses, family attitude towards treatment, adverse reactions to chemotherapy, and whether they have chronic diseases were all statistically significant (P<0.05), while the FFS-A scores of other factors were not statistically significant (P>0.05). According to Pearson analysis, the BFS-A score of patients with malignant hematological diseases is positively correlated with the SUPPH score (P<0.05), and negatively correlated with the SPBS score (P<0.05). Multiple linear regression showed that occupation, family annual income, adverse reactions to chemotherapy, SUPPH, and SPBS all had a positive impact on the sense of disease benefit (P<0.05), with SUPPH being a positive impact and occupation, family annual income, adverse reactions to chemotherapy, and SPBS being a negative impact.Conclusion:The sense of disease benefit in patients with malignant hematological diseases is related to their profession, annual family income, adverse reactions to chemotherapy, SUPPH, and SPBS.
|